Article in The Journal of cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Ophélie DufrançaisInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0009-0006-0993-547X
Marianna PlozzaInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0009-0008-5489-5360
Marie Juzans *Children's Hospital of Philadelphia Research Institute, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA, USA.ORCID 0009-0004-7665-8930
Arnaud Métais *Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0002-9538-0338
Sarah C MonardInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0001-7149-312X
Pierre-Jean BordignonInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0003-4073-8117
Perrine VerdysInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0009-0002-4365-9895
Thibaut SanchezInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0003-3087-8132
Martin BergertCell Biology and Biophysics Unit, European Molecular Biology Laboratory , Heidelberg, Germany.ORCID 0000-0002-3222-8929
Christopher J PanebiancoDepartment of Orthopaedic Surgery and Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8683-5743
Rémi MascarauInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0002-7009-2786
Rémi GenceCentre de Recherches en Cancérologie de Toulouse, Inserm UMR1037 and Institut Universitaire du Cancer de Toulouse - Oncopôle , Toulouse, France.ORCID 0000-0003-0747-3540
Gaëlle ArnaudInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0009-0005-1615-1553
Myriam Ben NejiInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0009-0008-7414-349X
Isabelle Maridonneau-PariniInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0003-0189-0976
Véronique Le CabecInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0002-0204-0976
Joel D BoerckelDepartment of Orthopaedic Surgery and Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-3126-3025
Nathan J PavlosSchool of Biomedical Sciences, The University of Western Australia , Nedlands, Australia.ORCID 0000-0001-7003-188X
Alba Diz-MuñozCell Biology and Biophysics Unit, European Molecular Biology Laboratory , Heidelberg, Germany.ORCID 0000-0001-6864-8901
Frédéric LagarrigueInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0002-4660-8666
Renaud PoinclouxInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0003-2884-1744
Janis K BurkhardtChildren's Hospital of Philadelphia Research Institute, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA, USA.ORCID 0000-0002-8176-1375
Brigitte Raynaud-Messina *Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0009-0000-1512-0871
Christel Vérollet *Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier (UT3) , Toulouse, France.ORCID 0000-0002-1079-9085
Funding
University of Pennsylvania Postdoctoral Opportunities in Research and TeachingK12GM081259 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Janis K. Burkhardt · 2007 to 2026
$20.1M
Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application)P30AR069619 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI LOUIS J SOSLOWSKY · 2016 to 2026
$9.1M
Mechanobiology of the immune synapse: signal integration via actin dynamicsR01AI147118 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI BURKHARDT, JANIS K. · 2021 to 2025
$2.1M
Centre National de la Recherche ScientifiqueCIHR PJT-1620109European Molecular Biology LaboratoryFondation pour la recherche contre le cancerFondation pour la Recherche Médicale EQU202303016313Fondation Toulouse Cancer SantéFoundation F. Initiativas par Fondation Fonroga ToulouseFrench National Research Agency ANR-10-INBS-04French National Research Agency ANR16-CE13-0005-01French National Research Agency ANR-18-EURE-0003French National Research Agency ANR-20-CE14-0037French National Research Agency ANR DFG 2020 JA-3038/2-1INSERMInstitut National de la Santé et de la Recherche MédicaleLa Ligue contre le CancerNational Health & Medical Research Council of Australia APP2020097National Health & Medical Research Council of Australia APP2029078NIAID NIH HHS R01 AI147118NIAMS NIH HHS P30 AR069619NIGMS NIH HHS K12 GM081259NIH HHS 2K12GM081259-16NIH HHS P30 AR069619NIH HHS R01 AI147118Toulouse Université, La Ligue contre le cancer par Toulouse Université, CARe doctoral schoolToulouse Université Paul SabatierUniversité Toulouse III - Paul Sabatier (UT3)Wellcome Trust
6 · The paper itself
Abstract
Cell-cell fusion is an evolutionarily conserved process that is essential for many functions, including the formation of bone-resorbing multinucleated osteoclasts. Osteoclast multinucleation involves dynamic interactions between the actin cytoskeleton and the plasma membrane that are still poorly characterized. We found that moesin, a cytoskeletal linker protein member of the Ezrin, radixin, and moesin (ERM) protein family, plays a critical role in both osteoclast fusion and function. Moesin inhibition favors osteoclast multinucleation as well as HIV-1- and inflammation-induced cell fusion. Accordingly, moesin depletion decreases membrane-to-cortex attachment and enhances the formation of tunneling nanotubes, F-actin-based intercellular bridges triggering cell-cell fusion. In addition, moesin regulates the formation of the sealing zone, a key structure determining osteoclast bone resorption area, and thus controls bone degradation via a β3-integrin/RhoA/SLK pathway. Finally, moesin-deficient mice have reduced bone density and increased osteoclast abundance and activity. These findings provide a better understanding of cell-cell fusion and osteoclast biology, opening new opportunities to specifically target osteoclasts in bone disease therapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Moesin controls cell-cell fusion and osteoclast function. · full record | OpenQuestion